IP Library Granted Patent US 8,410,175
Granted Patent B2
US 8,410,175 · App. 12/318,061 · Granted Apr 2, 2013

Anticancer effect enhancer

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,410,175
App. No.
12/318,061
Granted
Apr 2, 2013
Kind
B2
Abstract

An object of the present invention is to provide an enhancing agent for effect of anticancer agent for achieving an excellent therapeutic effect on cancer. The enhancing agent for effect of anticancer agent according to the present invention which is a solving means therefor is characterized in that a nitric oxide donor is an effective ingredient. In accordance with the present invention, an excellent therapeutic effect is able to be achieved on non-small cell lung cancer which is still in such a state that no effective therapeutic method has been established yet for a progressive cancer which is not operable and is one of cancers where chemotherapy is most difficult to apply.

Claims (6)

1. A method of cancer treatment, comprising:

administering 1) nitroglycerin at a dosage rate of 1 to 50 mg/day by transdermal administration and 2) a platinum-based anticancer agent to a cancer patient having non-small cell lung cancer or colon cancer.

2. The method of claim 1 , wherein the non-small cell lung cancer is adenocarcinoma.

3. The method of claim 1 , wherein administration of a course of chemotherapy with the platinum-based anticancer agent begins after the first administration of the nitroglycerin.

4. The method of claim 3 , wherein the nitroglycerin is administered at least daily from the first administration of nitroglycerin, to the finish of administration of the platinum-based anticancer agent in the course of chemotherapy.

5. The method of claim 1 , wherein at least one anticancer agent selected from the group consisting of antimetabolite, alkylating agent, anticancer antibiotic, microtubule-acting agent, topoisomerase inhibitor and alkaloidal anticancer agent is further administered.